title: In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections.
abstract: Human cytomegalovirus (HCMV) infection does not generally cause problems in the immunocompetent adult but can result in severe clinical disease in the fetus, neonate, and immunocompromised host. Ganciclovir (GCV), the agent currently used to treat most HCMV infections, has resulted in much therapeutic success; however, efficacy remains suboptimal. Therefore, there is still a need to develop new compounds for use against HCMV infections. In the present study, several Z- and E-series methylenecyclopropane analogues and their phosphoroalaninate prodrugs were tested initially for activity against HCMV, strain AD169, and murine cytomegalovirus (MCMV) in vitro. Many were found to exhibit efficacy comparable to that of GCV against HCMV in plaque assays and were active against MCMV as well. The compounds were also tested for efficacy against herpes simplex virus types 1 and 2, varicella-zoster virus, and Epstein-Barr virus, and some had levels of activity that were comparable to that of acyclovir. In addition, the compounds synguanol (QYL-438) and 2-amino-6-cyclopropylamino analogue (QYL-769) were chosen for further evaluation and were found to be effective against additional laboratory and clinical isolates of HCMV and GCV-resistant isolates. QYL-438 and QYL-769 were found to be nontoxic in human and mouse fibroblasts and were considerably less toxic than GCV in granulocyte macrophage CFUs and erythroid burst-forming units. These results provide evidence for the high activity of some of these methylenecyclopropane analogues against various herpesviruses, particularly HCMV, in tissue culture and suggest that further evaluation is warranted to determine their potential for use in future clinical studies.
authors.affiliation: University of Alabama School of Medicine, Birmingham, Alabama, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Rybak
authors.forename: C B
authors.initials: CB
authors.lastname: Hartline
authors.forename: Y L
authors.initials: YL
authors.lastname: Qiu
authors.forename: J
authors.initials: J
authors.lastname: Zemlicka
authors.forename: E
authors.initials: E
authors.lastname: Harden
authors.forename: G
authors.initials: G
authors.lastname: Marshall
authors.forename: J P
authors.initials: JP
authors.lastname: Sommadossi
authors.forename: E R
authors.initials: ER
authors.lastname: Kern
mesh_terms: D000328:Adult; D000818:Animals; D003521:Cyclopropanes; D003587:Cytomegalovirus / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D051379:Mice; D009705:Nucleosides / Q000494:pharmacology / Q000627:therapeutic use*; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D003521:Cyclopropanes; D009705:Nucleosides; D011355:Prodrugs